• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Akt 依赖的糖酵解驱动的脂肪生成支持肺动脉高压中人类肺动脉平滑肌细胞的增殖和存活。

Akt-Dependent Glycolysis-Driven Lipogenesis Supports Proliferation and Survival of Human Pulmonary Arterial Smooth Muscle Cells in Pulmonary Hypertension.

作者信息

Jiang Lifeng, Goncharov Dmitry A, Shen Yuanjun, Lin Derek, Chang Baojun, Pena Andressa, DeLisser Horace, Goncharova Elena A, Kudryashova Tatiana V

机构信息

Lung Center, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, School of Medicine, University of California, Davis, Davis, CA, United States.

Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, United States.

出版信息

Front Med (Lausanne). 2022 Jun 28;9:886868. doi: 10.3389/fmed.2022.886868. eCollection 2022.

DOI:10.3389/fmed.2022.886868
PMID:35836951
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9274086/
Abstract

Hyper-proliferation of pulmonary arterial vascular smooth muscle cells (PAVSMC) is an important pathological component of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH). Lipogenesis is linked to numerous proliferative diseases, but its role in PAVSMC proliferation in PAH remains to be elucidated. We found that early-passage human PAH PAVSMC had significant up-regulation of key fatty acids synthesis enzymes ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN), and increased unstimulated proliferation compared to control human PAVSMC. Treatment with an allosteric ACC inhibitor 5-tetradecyloxy-2-furoic acid (TOFA) significantly decreased proliferation and induced apoptosis of human PAH PAVSMC. Intracellular lipid content and proliferation of PAH PAVSMC were not reduced by incubation in lipid-depleted media but suppressed by a non-metabolizable analog of glucose 2-Deoxy-D-glucose (2-DG) and partially restored by addition of pyruvate. Protein kinase Akt was upregulated in human PAH PAVSMC in a sirtuin 7 (SIRT7)- and c-Jun N-terminal kinase (JNK)-dependent manner. Pharmacological inhibition of Akt down-regulated ACLY and ACC, significantly reduced intracellular lipid content, inhibited proliferation and induced apoptosis of human PAH PAVSMC. Taken together, these data demonstrate that human PAH PAVSMC have up-regulated lipogenesis, which is supported in an Akt- and glycolysis-dependent manner and is required for increased proliferation and survival. Our data suggest that there is a mechanistic link between glycolysis, lipogenesis, and the proliferation of human PAH PAVSMC and call for further studies to determine the potential attractiveness of a SIRT7/JNK-Akt-lipogenesis axis as a target pathway to inhibit PAVSMC hyper-proliferation in PAH.

摘要

肺动脉血管平滑肌细胞(PAVSMC)的过度增殖是肺动脉高压(PAH)中肺血管重塑的一个重要病理组成部分。脂肪生成与多种增殖性疾病相关,但其在PAH中PAVSMC增殖中的作用仍有待阐明。我们发现,与对照人PAVSMC相比,早期传代的人PAH PAVSMC中关键脂肪酸合成酶ATP-柠檬酸裂解酶(ACLY)、乙酰辅酶A羧化酶(ACC)和脂肪酸合酶(FASN)显著上调,且未受刺激的增殖增加。用变构ACC抑制剂5-十四烷氧基-2-呋喃甲酸(TOFA)处理可显著降低人PAH PAVSMC的增殖并诱导其凋亡。在无脂培养基中孵育并未降低PAH PAVSMC的细胞内脂质含量和增殖,但可被葡萄糖非代谢类似物2-脱氧-D-葡萄糖(2-DG)抑制,并通过添加丙酮酸部分恢复。蛋白激酶Akt在人PAH PAVSMC中以沉默调节蛋白7(SIRT7)和c-Jun氨基末端激酶(JNK)依赖的方式上调。对Akt的药理学抑制下调了ACLY和ACC,显著降低了细胞内脂质含量,抑制了人PAH PAVSMC的增殖并诱导其凋亡。综上所述,这些数据表明人PAH PAVSMC的脂肪生成上调,这以Akt和糖酵解依赖的方式得到支持,并且是增殖和存活增加所必需的。我们的数据表明,糖酵解、脂肪生成与人PAH PAVSMC的增殖之间存在机制联系,并呼吁进一步研究以确定SIRT7/JNK-Akt-脂肪生成轴作为抑制PAH中PAVSMC过度增殖的靶途径的潜在吸引力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/b2bc7030794a/fmed-09-886868-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/d759f95ba704/fmed-09-886868-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/48b8f489d923/fmed-09-886868-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/1924e9f86456/fmed-09-886868-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/f053a3af1939/fmed-09-886868-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/a466951b7efd/fmed-09-886868-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/b2bc7030794a/fmed-09-886868-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/d759f95ba704/fmed-09-886868-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/48b8f489d923/fmed-09-886868-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/1924e9f86456/fmed-09-886868-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/f053a3af1939/fmed-09-886868-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/a466951b7efd/fmed-09-886868-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bd/9274086/b2bc7030794a/fmed-09-886868-g006.jpg

相似文献

1
Akt-Dependent Glycolysis-Driven Lipogenesis Supports Proliferation and Survival of Human Pulmonary Arterial Smooth Muscle Cells in Pulmonary Hypertension.Akt 依赖的糖酵解驱动的脂肪生成支持肺动脉高压中人类肺动脉平滑肌细胞的增殖和存活。
Front Med (Lausanne). 2022 Jun 28;9:886868. doi: 10.3389/fmed.2022.886868. eCollection 2022.
2
Inhibitory Antibodies against Activin A and TGF-β Reduce Self-Supported, but Not Soluble Factors-Induced Growth of Human Pulmonary Arterial Vascular Smooth Muscle Cells in Pulmonary Arterial Hypertension.抗激活素 A 和 TGF-β 抗体可减少人肺动脉平滑肌细胞在肺动脉高压中的自分泌,但不能减少可溶性因子诱导的生长。
Int J Mol Sci. 2018 Sep 28;19(10):2957. doi: 10.3390/ijms19102957.
3
Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.哺乳动物雷帕霉素靶蛋白复合物 2(mTORC2)协调肺动脉平滑肌细胞代谢、增殖和在肺动脉高压中的存活。
Circulation. 2014 Feb 25;129(8):864-74. doi: 10.1161/CIRCULATIONAHA.113.004581. Epub 2013 Nov 22.
4
Profiling the role of mammalian target of rapamycin in the vascular smooth muscle metabolome in pulmonary arterial hypertension.分析雷帕霉素哺乳动物靶点在肺动脉高压血管平滑肌代谢组中的作用。
Pulm Circ. 2015 Dec;5(4):667-80. doi: 10.1086/683810.
5
HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.HIPPO-整合素连接激酶相互作用调控肺动脉高压中的自我持续增殖与存活
Am J Respir Crit Care Med. 2016 Oct 1;194(7):866-877. doi: 10.1164/rccm.201510-2003OC.
6
Differential effects of integrin-linked kinase inhibitor Cpd22 on severe pulmonary hypertension in male and female rats.整合素连接激酶抑制剂Cpd22对雄性和雌性大鼠重度肺动脉高压的不同作用
Pulm Circ. 2020 Feb 12;10(1):2045894019898593. doi: 10.1177/2045894019898593. eCollection 2020 Jan-Mar.
7
Regulatory effects of Prohibitin 1 on proliferation and apoptosis of pulmonary arterial smooth muscle cells in monocrotaline-induced PAH rats.抑素 1 对野百合碱诱导肺动脉高压大鼠肺动脉平滑肌细胞增殖和凋亡的调控作用。
Life Sci. 2020 Jun 1;250:117548. doi: 10.1016/j.lfs.2020.117548. Epub 2020 Mar 12.
8
NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.NMDA 型谷氨酸受体激活促进血管重塑和肺动脉高压。
Circulation. 2018 May 29;137(22):2371-2389. doi: 10.1161/CIRCULATIONAHA.117.029930. Epub 2018 Feb 14.
9
Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling.纤溶酶原激活物抑制剂-2 通过 PI3K/Akt 和 ERK 信号通路抑制肺动脉高压中的肺动脉平滑肌细胞增殖。
Exp Cell Res. 2021 Jan 1;398(1):112392. doi: 10.1016/j.yexcr.2020.112392. Epub 2020 Nov 21.
10
Platelet-Derived TGF (Transforming Growth Factor)-β1 Enhances the Aerobic Glycolysis of Pulmonary Arterial Smooth Muscle Cells by PKM2 (Pyruvate Kinase Muscle Isoform 2) Upregulation.血小板衍生的 TGF-β1 通过上调 PKM2(丙酮酸激酶肌肉同工酶 2)增强肺动脉平滑肌细胞的有氧糖酵解。
Hypertension. 2022 May;79(5):932-945. doi: 10.1161/HYPERTENSIONAHA.121.18684. Epub 2022 Mar 2.

引用本文的文献

1
HNRNPA2B1: a novel target in pulmonary arterial hypertension.HNRNPA2B1:肺动脉高压的一个新靶点。
Front Cardiovasc Med. 2025 Jul 9;12:1497938. doi: 10.3389/fcvm.2025.1497938. eCollection 2025.
2
Signaling pathways and targeted therapy for pulmonary hypertension.肺动脉高压的信号通路与靶向治疗
Signal Transduct Target Ther. 2025 Jul 1;10(1):207. doi: 10.1038/s41392-025-02287-8.
3
Roles of posttranslational modifications in lipid metabolism and cancer progression.翻译后修饰在脂质代谢和癌症进展中的作用。

本文引用的文献

1
Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival.非经典的 HIPPO/MST 信号通过 BUB3 和 FOXO 驱动肺血管细胞的生长和存活。
Circ Res. 2022 Mar 4;130(5):760-778. doi: 10.1161/CIRCRESAHA.121.319100. Epub 2022 Feb 7.
2
Targeting PI3K/Akt signal transduction for cancer therapy.针对 PI3K/Akt 信号转导通路的癌症治疗策略。
Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5.
3
Pulmonary Arterial Hypertension.肺动脉高压
Biomark Res. 2024 Nov 18;12(1):141. doi: 10.1186/s40364-024-00681-y.
4
Glycolysis modulation: New therapeutic strategies to improve pulmonary hypertension (Review).糖酵解调节:改善肺动脉高压的新治疗策略(综述)。
Int J Mol Med. 2024 Dec;54(6). doi: 10.3892/ijmm.2024.5439. Epub 2024 Oct 18.
5
What Is All of the Hype About? Hypusine Signaling as a Driver of Pulmonary Hypertension.炒作的是什么?hypusine信号传导作为肺动脉高压的驱动因素。
Am J Respir Crit Care Med. 2024 Jun 1;209(11):1298-1300. doi: 10.1164/rccm.202401-0195ED.
6
Endothelium-specific SIRT7 targeting ameliorates pulmonary hypertension through Krüpple-like factor 4 deacetylation.内皮细胞特异性 SIRT7 靶向治疗通过 Krüpple 样因子 4 去乙酰化改善肺动脉高压。
Cardiovasc Res. 2024 Mar 30;120(4):403-416. doi: 10.1093/cvr/cvae011.
7
SIRT7: the seventh key to unlocking the mystery of aging.SIRT7:揭开衰老之谜的第七把钥匙。
Physiol Rev. 2024 Jan 1;104(1):253-280. doi: 10.1152/physrev.00044.2022. Epub 2023 Sep 7.
8
Identification of Zip8-correlated hub genes in pulmonary hypertension by informatic analysis.通过信息学分析鉴定肺动脉高压中与 Zip8 相关的枢纽基因。
PeerJ. 2023 Aug 28;11:e15939. doi: 10.7717/peerj.15939. eCollection 2023.
9
Single Nucleotide Polymorphism rs9277336 Controls the Nuclear Alpha Actinin 4-Human Leukocyte Antigen-DPA1 Axis and Pulmonary Endothelial Pathophenotypes in Pulmonary Arterial Hypertension.单核苷酸多态性 rs9277336 控制核 α 辅肌动蛋白 4-人类白细胞抗原-DPA1 轴和肺动脉高压的肺血管内皮病理表型。
J Am Heart Assoc. 2023 Apr 4;12(7):e027894. doi: 10.1161/JAHA.122.027894. Epub 2023 Mar 28.
N Engl J Med. 2021 Dec 16;385(25):2361-2376. doi: 10.1056/NEJMra2000348.
4
Combined intermittent fasting and ERK inhibition enhance the anti-tumor effects of chemotherapy via the GSK3β-SIRT7 axis.联合间歇性禁食和 ERK 抑制通过 GSK3β-SIRT7 轴增强化疗的抗肿瘤作用。
Nat Commun. 2021 Aug 25;12(1):5058. doi: 10.1038/s41467-021-25274-3.
5
Extracellular matrix degradation pathways and fatty acid metabolism regulate distinct pulmonary vascular cell types in pulmonary arterial hypertension.细胞外基质降解途径和脂肪酸代谢调节肺动脉高压中不同的肺血管细胞类型。
Pulm Circ. 2021 Mar 2;11(1):2045894021996190. doi: 10.1177/2045894021996190. eCollection 2021 Jan-Mar.
6
Quality of life of patients with pulmonary arterial hypertension: a meta-analysis.肺动脉高压患者的生活质量:一项荟萃分析。
Eur Rev Med Pharmacol Sci. 2021 Aug;25(15):4983-4998. doi: 10.26355/eurrev_202108_26455.
7
SIRT7: a sentinel of genome stability.SIRT7:基因组稳定性的哨兵。
Open Biol. 2021 Jun;11(6):210047. doi: 10.1098/rsob.210047. Epub 2021 Jun 16.
8
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?AKT抑制剂:对抗乳腺癌的新武器?
Front Pharmacol. 2021 Apr 29;12:662232. doi: 10.3389/fphar.2021.662232. eCollection 2021.
9
Sirt7 Deficiency Attenuates Neointimal Formation Following Vascular Injury by Modulating Vascular Smooth Muscle Cell Proliferation.Sirt7 缺乏通过调节血管平滑肌细胞增殖来减轻血管损伤后的新内膜形成。
Circ J. 2021 Nov 25;85(12):2232-2240. doi: 10.1253/circj.CJ-20-0936. Epub 2021 Mar 5.
10
Metabolism in Pulmonary Hypertension.肺动脉高压中的代谢
Annu Rev Physiol. 2021 Feb 10;83:551-576. doi: 10.1146/annurev-physiol-031620-123956.